---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-024799"
form_type: "8-K"
ticker: "GYRE"
cik: "0001124105"
company_name: "GYRE THERAPEUTICS, INC."
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T08:42:58.403862+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "medium"
source: SEC EDGAR
---

# Gyre Pharma unit acquires rights to generic Nintedanib, competing drug to ETUARY, for IPF/category

## Summary
- Gyre Pharmaceuticals (GYRE subsidiary) signed a comprehensive agreement with Jiangsu Wangao to acquire rights to generic Nintedanib, a competitor to ETUARY.
- ETUARY sales grew 15-20% annually; IPF drug market in China expected to reach ¥127.4B by 2031 per Frost & Sullivan.
- Annual sales of Nintedanib expected to exceed ¥4 billion if not included in centralized procurement system.
- Acquisition enhances Gyre's leading position in pulmonary fibrosis and adds a new product for IPF and similar diseases.

## SEC filing metadata
- accession: 0001140361-24-024799
- form_type: 8-K
- ticker: GYRE
- cik: 0001124105
- company_name: GYRE THERAPEUTICS, INC.
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: medium
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1124105/000114036124024799/0001140361-24-024799-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1124105/000114036124024799/ef20028687_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-024799
- JSON: https://secwatch.observer/filing/0001140361-24-024799.json
- Plain text: https://secwatch.observer/filing/0001140361-24-024799.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.